Skip to Main Content

On Target is a recurring feature from STAT that dives deep into the most promising drug targets in oncology. 

Oncologists may soon have a new immuno-oncology target in their arsenal. Experts expect the Food and Drug Administration to soon approve relatlimab, a Bristol Myers Squibb drug that binds to a cancer target called LAG-3, making it the first new immune checkpoint target in nearly a decade.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment